Last updated: February 17, 2026
What is the Drug?
NDC 51862-0868 corresponds to Apretude (cabotegravir extended-release injectable suspension). It is used for HIV pre-exposure prophylaxis (PrEP), designed for administration every two months. Approved by the FDA in December 2021, it serves as an alternative to daily oral medications.
Market Overview
Current Market Landscape
The PrEP market, particularly for HIV prevention, experienced accelerated growth due to increased awareness and expanded insurance coverage. The market for injectable PrEP drugs is emerging, with Apretude positioned as a primary product following the approval.
Competitive Positioning
- Key Competitors: Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide). Both are oral daily regimens.
- Differentiation: Apretude offers a bi-monthly injection, which improves adherence compared to daily pills. This factor is critical, as adherence impacts efficacy and market penetration.
Adoption Drivers
- Patient Preferences: Preference for less frequent dosing.
- Insurance Coverage: Increasing coverage under Medicaid and private insurers.
- Provider Acceptance: Growing number of clinics adopting injectable PrEP protocols.
Barriers
- Cost: High price point may restrict access.
- Injection Site Reactions: Mostly mild but may affect patient acceptance.
- Regulatory and Reimbursement Strategies: Dependence on payer decisions to maximize market penetration.
Price Projections
Current Pricing Data
- List Price: Estimated at approximately $3,800 per injection (per dose), equating to over $22,800 annually assuming bi-monthly injections.
Comparative Analysis
| Drug |
Dosage |
Cost per Dose |
Annual Cost |
Administration Schedule |
| Apretude |
600 mg (injectable) |
~$3,800 |
~$22,800 |
Every 2 months (6 doses/year) |
| Truvada (oral) |
300 mg/200 mg daily |
~$2,000/month |
~$24,000 |
Daily |
| Descovy (oral) |
300 mg/200 mg daily |
~$2,100/month |
~$25,200 |
Daily |
Short-term Price Trends (Next 2 Years)
- Prices are expected to remain stable initially due to manufacturing costs.
- Negotiated discounts with insurers could reduce patient out-of-pocket costs.
- Potential for price reduction driven by competition and inclusion in broad PrEP programs.
Long-term Price Outlook (Next 5 Years)
- Market competition and increased biosimilar or generic injector development could pressure prices downward.
- Pricing could fall to approximately $2,500–$3,000 per injection if margins are compressed.
- Incorporation into value-based reimbursement models could further influence pricing structures.
Market Penetration and Revenue Projections
2023-2024 Estimates
- Market Penetration: Given early adoption, estimates project 10-15% of the PrEP market share within two years.
- Revenue Projection: With sales volume of 100,000 doses in 2024, revenues could reach approximately $380 million at current pricing.
2025-2027 Outlook
- As adoption increases, sales volume could grow 20-30% annually.
- A conservative estimate projects annual revenue reaching $700 million by 2027 if pricing stabilizes and market share expands to 25-30%.
Key Factors Impacting Pricing & Market Dynamics
- Reimbursement policies: Coverage expansions and negotiated discounts heavily influence net prices.
- Patient adherence and preferences: Higher acceptance of injections can accelerate adoption.
- Regulatory changes: Potential approvals for broader indications could expand the market.
- Manufacturing costs and competition: Advances in biosimilars could pressure pricing downward.
Summary
| Aspect |
Data/Projection |
| List Price per Injection |
~$3,800 |
| Estimated Annual Revenue (2024) |
~$380 million |
| Market Share (by 2027) |
25-30% of PrEP market |
| Speed of Adoption |
Moderate, influenced by insurance and provider policies |
| Long-term Price Trend |
Potential decline to $2,500–$3,000 per injection in 5 years |
Key Takeaways
- Apretude is positioned as a key injectable PrEP with rapid growth potential.
- Current price is high but may decrease as competition and biosTranscript-based options emerge.
- Market penetration depends on insurance reimbursement, patient acceptance, and provider adoption policies.
- Revenue projections are optimistic if widespread usage occurs, with potential to reach hundreds of millions annually.
- Pricing strategies and payer negotiations will significantly influence profitability.
FAQs
1. Will the price of Apretude decrease over time?
Likely, as biosimilar options emerge and competition increases, prices could decline to approximately $2,500–$3,000 per injection within five years.
2. How does Apretude's pricing compare with oral PrEP?
The annual cost of Apretude (~$22,800) is comparable to Truvada and Descovy but offers convenience with less frequent dosing, which may justify current pricing for some patients.
3. What factors could accelerate market penetration?
Insurance coverage expansion, increased provider familiarity, and patient preference for injections improve adoption rates.
4. How significant are reimbursement policies in shaping revenue?
Reimbursement and payer negotiations are crucial; better coverage reduces out-of-pocket costs and boosts sales.
5. Are there regional market differences affecting pricing?
Yes. Developed markets like the US and Europe are adopting injectable PrEP more rapidly, impacting revenues differently across regions.
Sources:
[1] FDA. Approved Drug Products: Apretude (cabotegravir extended-release injectable suspension). December 2021.
[2] IQVIA. Market Data and Pricing Reports, 2023.
[3] CDC. HIV Pre-Exposure Prophylaxis (PrEP) Usage and Trends. 2022.
